Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

  title={Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients},
  author={Juergen Floege and Adrian Constantin Covic and Markus Ketteler and Johannes F. E. Mann and Anjay Rastogi and Bruce S Spinowitz and Edward M.F. Chong and Sylvain Gaillard and Laura J. Lisk and Stuart M. Sprague},
  booktitle={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
BACKGROUND Hyperphosphatemia necessitates the use of phosphate binders in most dialysis patients. Long-term efficacy and tolerability of the iron-based phosphate binder, sucroferric oxyhydroxide (previously known as PA21), was compared with that of sevelamer carbonate (sevelamer) in an open-label Phase III extension study. METHODS In the initial Phase III study, hemo- or peritoneal dialysis patients with hyperphosphatemia were randomized 2:1 to receive sucroferric oxyhydroxide 1.0-3.0 g/day… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
25 Citations
17 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 25 extracted citations


Publications referenced by this paper.
Showing 1-10 of 17 references

Efficacy and safety of a novel iron-based phosphate binder in dialysis patients, in a Phase III study

  • J Floege, AC Covic, KettelerM
  • Kidney Int
  • 2014
Highly Influential
10 Excerpts

Efficacy and safety of the novel ironbased phosphate binder PA21 in peritoneal- and haemodialysis-dependent CKD patients

  • J Floege, A Covic, M Ketteler
  • Poster presented at the 11th European Peritoneal…
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…